DNA Vaccine Technology to Rapidly Produce Cocktails of Polyclonal Antibodies to Neutralize Lethal Viruses of Military Importance

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-13-C-0041
Agency Tracking Number: A12A-028-0109
Amount: $99,995.00
Phase: Phase I
Program: STTR
Awards Year: 2013
Solicitation Year: 2012
Solicitation Topic Code: A12a-T028
Solicitation Number: 2012.A
Small Business Information
Aldevron
3233 15th Street South, Fargo, ND, -
DUNS: 048764943
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 John Ballantyne
 CSO
 (701) 297-9256
 jb@aldevron.com
Business Contact
 Ronald Robson
Title: Chief Operating Officer
Phone: (701) 297-9256
Email: robson@aldevron.com
Research Institution
 US Army Medical Research Institute
 Jay Hooper
 1425 Porter Street
Frederick, MD, 21702-9211
 (301) 619-4101
 Federally funded R&D center (FFRDC)
Abstract
In this Phase I STTR proposal we will determine the ruggedness of the genetic immunization technique in the production of duck egg derived immunoglobulin; specifically the natural F(ab")2 analog, IgY^Fc. We have already demonstrated that potently neutralizing duck egg antibodies generated with an early candidate Andes virus DNA vaccine, delivered via intramuscular electroporation, can protect after lethal challenge. We now seek to optimize the elements necessary to deploy a commercially viable platform system for the rapid production of passive immunity products as countermeasures to emerging viral threats. Mammalian or avian (Mallard duck) codon optimized Andes virus DNA vaccine variants of the original will be administered to ducks utilizing electroporation or a needle-free device. An increased potency and/or response frequency along with a decreased response time would represent a significant and enabling progression in the field. The work will be coupled with a small parallel study in sheep with Andes and Junin virus DNA vaccine candidates. Endpoints as measures of success will be determined by known correlates of protection using plaque reduction neutralizing tests and pseudoviral assays. Simple reactogenicity studies will also be performed with all full-length and despeciated immunoglobulin"s and the results compared to licensed polyclonal and monoclonal products.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government